Compare Abeona Therapeutics Inc (ABEO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while abrdn Physical Palladium Shares ETF trades at $22.14. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | PALL | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.23 | $37.18 |
52-Week Low | $4.17 | $19.96 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PALL trades at $23.15, up 1.05% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. A 1-for-5 stock split is scheduled for May 18, 2026. Recent news highlights palladium's price weakness as a potential buying opportunity, citing supply risks and industrial demand. The stock faces headwinds from Federal Reserve rate hike expectations and weaker investment demand.
The outlook remains cautious due to bearish technicals and macroeconomic pressures, though some analysts see value at current levels. Key risks include commodity price volatility and interest rate sensitivity. Investors should weigh the ETF's exposure to palladium's supply-demand dynamics against broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
